Impact of Bone Metastases and Actionable Genetic Alterations in Biliary Tract Cancer
Open Access
Abstract
Background: Bone metastasis (BM) prevalence is underreported in biliary tract cancers (BTC). This study aimed to assess BM prevalence in a real-world BTC population, alongside examining its relationship to prognosis and genomic alterations. Methods: Patients with histology-proven BTC as reviewed at a university cancer centre between January 2019 and August 2022 were assessed. Data extracted from records included BTC subtype, molecular profiling and systemic anti-cancer therapy (SACT) use. Stratification by BTC subtype and metastasis sites occurred. Median overall survival (mOS) was defined as time from relapse or metastases to death. Survival analysis was conducted using the Cox Proportional Hazard model. Results: Of 197 patients, 74 (37.6%) had intrahepatic and 67 (34%) had extrahepatic cholangiocarcinoma. Thirty-four patients had BM (17.3%), with 14 identified at initial diagnosis. OS was not influenced by bone (HR 1.15; p = 0.48) or liver metastases (HR 1.09; p = 0.6). Stratifying for age and gender, no significant difference in OS was observed. Actionable alterations were equally likely in patients with (52.4%) and without BM (58.5%). Age of BTC onset (p < 0.005). Conclusions: In advanced BTC, BM do not affect OS. Across all cohorts, actionable alterations improved OS when treated with matched SACT.Keywords
This publication has 32 references indexed in Scilit:
- 279MO Three-year survival, safety and extended long-term survivor (eLTS) analysis from the phase III TOPAZ-1 study of durvalumab (D) plus chemotherapy in biliary tract cancer (BTC)Annals of Oncology, 2024
- Cholangiocarcinoma across England: Temporal changes in incidence, survival and routes to diagnosis by region and level of socioeconomic deprivationJHEP Reports, 2023
- Characteristics and clinical outcomes in young‐onset cholangiocarcinomaCancer Medicine, 2023
- Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Age trends in biliary tract cancer incidence by anatomical subtype: A Swedish cohort studyEuropean Journal of Cancer, 2022
- Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA RegistryJournal of Hepatology, 2022
- How I treat biliary tract cancerESMO Open, 2022
- Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With SurvivalJAMA Network Open, 2021
- Current standards and future perspectives in adjuvant treatment for biliary tract cancersCancer Treatment Reviews, 2020
- Bone metastases in biliary cancers: A multicenter retrospective surveyJournal of Bone Oncology, 2018